** Shares of drug developer Anika Therapeutics ANIK.O fall 2.7% to $16.54 in afternoon trade
** Company says it completes planned divestiture of its Parcus Medical business to Medacta Group MOVE.S to focus on its core hyaluronic acid technology for osteoarthritis pain management and expand its regenerative solutions portfolio
** Anika says the sale was completed with total cash consideration received at closing for an undisclosed amount
** Company reported its plan to divest Parcus Medical in October 2024
** ANIK down 34.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。